The Study of the Fixed Dose Combination of Lisinopril with Prolonged Indopamide (FIXLINDA) with Daily Blood Pressure Monitoring and Diuresis in Hypertensive Patients

Author:

Savenkov M. P.1,Ivanov S. N.2,Mikhaylusova M. P.1,Borschevskaya M. V.1,Savenkova A. M.1,Kozachenko N. Y.1,Sherifova E. S.2

Affiliation:

1. Pirogov Russian National Research Medical University

2. War Veterans Hospital No.2 of the Moscow Health Department

Abstract

Аim. To study the efficacy, tolerability and safety of using a fixed dose combination of an ACE inhibitor lisinopril with a prolonged-action diuretic indapamide in patients with degree 1-2 hypertension.Material and methods. Patients (n = 32) with uncontrolled 1-2 degrees hypertension, moderate or high cardiovascular risk, without severe comorbid diseases, who were prescribed a fixed dose combination of lisinopril (5, 10 or 20 mg) and indapamide (1.5 mg) were included in the observational study. All patients had home monitoring of blood pressure and diuresis, as well as assessment of subjective tolerance of treatment and registration of adverse events within 3 months of observation. Assessment of changes in circadian fluctuations in blood pressure and diuresis, the frequency of achieving the target blood pressure at the outpatient stage, as well as the subjective tolerance of treatment and adverse events during a three-month follow-up.Results. Target blood pressure was achieved in 44.5% of patients taking the fixed dose combination of lisinopril 5 mg + prolonged-acting indapamide1.5 mg; 76.9% – in patients taking the combination of lisinopril 10 mg + indapamide 1.5 mg; 78,6% – in patients taking the combination of lisinopril 20 mg + indapamide 1.5 mg. The achieved antihypertensive effect was characterized by daily circadian stability, accompanied by an improvement in the initially impaired day and night diuretic profile (increase in the share of daytime diuresis by 29.6% and 22.3% with a decrease in the share of nighttime diuresis by 35% and 49% when using a combination with lisinopril 5 and 10 mg, respectively). The treatment was well tolerated by patients and did not cause the development of serious adverse events. Reported adverse events (non-intense dry cough, headache, general weakness) were transient and did not require correction or withdrawal of treatment.Conclusion. The fixed dose combination of the ACE inhibitor lisinopril (5, 10 or 20 mg) and the long-acting thiazide-like diuretic indapamide (1.5 mg) had good antihypertensive efficacy with improved circadian blood pressure and diuresis profiles, acceptable tolerance and safety of treatment, as well as a simple choice of doses of the drug components.

Publisher

Stolichnaya Izdatelskaya Kompaniyaizdat

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Reference19 articles.

1. Abdullaev R.Y., Sobol Y.S., Schiller N.B., Foster E. Modern echocardiography. Kharkiv: Fortuna Press; 1998 (In Russ.).

2. Rudoy A.S., Bova A.A., Nekhaychik T.A. Genetic aortopathies and structural anomalies of the heart. Moscow: GEOTAR-Media; 2017 (In Russ.).

3. Feed L.A., Lovy D., Levine R.A. et al. Mitral valve prolapse and atrial septal aneurysm: an evaluation in the Framingham. Am J Cardiol. 2002;89(11):1326-9. DOI:10.1016/S0002-9149(02)02340-8.

4. Nechaeva G.I., Martynov A.I. Connective tissue dysplasia: cardiovascular changes, modern approaches to diagnosis and treatment. Moscow: Medical Information Agency; 2017 (In Russ.).

5. Yetkin E., Atalay H., Ileri M. Atrial septal aneurysm: Prevalence and covariates in adults. Int J Cardiol. 2016;223:656-9. DOI:10.1016/j.ijcard.2016.08.220.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3